Kevin Weil’s Warp Sciences Raises $215 Million at $865 Million, Above August Talks

Warp Sciences, the startup founded by former OpenAI executive Kevin Weil to automate wet-lab chemistry with robots, has raised $215 million at an $865 million valuation, according to TechCrunch, which cited Weil’s announcement on X. Lightspeed led the round, with IVP, Premji Invest and Lux Capital participating.

The number to hold against it is the August one. Business Insider reported on Aug. 11 that Weil was seeking $150 million at a valuation of at least $750 million, citing sources, according to a summary on AI Weekly. The announced round is $65 million, or 43 percent, larger than that target, at a valuation 15 percent above the floor.

What changed between August and October

	Business Insider, Aug. 11	TechCrunch, Oct. 22
Amount	$150 million	$215 million
Valuation	At least $750 million	$865 million
Lead investor	Not named	Lightspeed
Status	Seeking, per sources	Announced by Weil on X

Neither outlet says whether $865 million is a pre-money or post-money valuation, and the difference matters. If it is post-money, the $215 million buys about 25 percent of the company. If it is pre-money, the same cheque buys about 20 percent. Both are our arithmetic, not a figure from either source.

TechCrunch reports the round as announced, not closed. No filing was available to confirm the amount, so the defensible statement is that Weil says the company has raised it.

What the robots are meant to do

TechCrunch describes Warp Sciences as building robots that make and test promising compounds that researchers identify, aimed at drug discovery. Human chemists will wear cameras and sensor gloves to train the robots on lab tasks, and the machines are meant to run around the clock.

Weil also wants to bring molecule synthesis back onshore. Biotech companies have often outsourced it to contractors in China, and TechCrunch names WuXi AppTec as an example.

The article names no customers, no lab sites and no robot count. A glove-trained system that performs a handful of reactions is a demonstration, and one that runs a customer’s synthesis queue overnight is a service. TechCrunch’s account does not say which stage Warp Sciences is at, and the company’s own materials were not available to this reporter.

Who is paying, and how that compares

Lux Capital also backs Flapping Airplanes, whose $1 billion Series A at a $6 billion valuation The Terminal covered earlier. Warp Sciences is priced at about one-seventh of that valuation, with a physical product to build.

Hardware changes the arithmetic. Robots in labs carry capital costs and failure modes that a pure software round does not. Compare the $66 million Series C for the CI infrastructure startup Blacksmith, which sells compute by the job rather than chemistry by the compound. The comparison is of shape only.

Weil’s earlier title is reported two ways. TechCrunch calls him a former OpenAI science lead; the AI Weekly summary of Business Insider calls him a former chief product officer who last led the company’s special projects group. This article uses neither as a credential for the company’s chemistry.

The next observable event is a first named customer or a disclosed lab site. Until one appears, the $865 million rests on the founder’s record and the investors’ conviction.